Epstein-Barr virus–positive, primary cutaneous marginal zone lymphoma, with transformation: Case report and review of the literature
American Journal of Clinical Pathology · 2025
DOI: 10.1093/ajcp/aqae124 ↗Kurz gefasst
Fallbericht in der Zeitschrift American Journal of Clinical Pathology, 2025. Verfasst von Lori Soma und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Beckman Research Institute, City of Hope Medical Center, Duarte, CA, US. Hauptthemen laut MEDLINE: Cell Transformation, Neoplastic, Epstein-Barr Virus Infections, Lymphoma, B-Cell, Marginal Zone, Plasmablastic Lymphoma. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 63 Literaturangaben. Gefördert von: Department of Pathology, City of Hope Medical Center.
Abstract (Originalsprache)
Introduction
Epstein-Barr Virus (EBV) positive primary cutaneous marginal zone lymphoma (PCMZL) is uncommon and subsequent transformation is rare.
Methods
We report a patient with EBV positive PCMZL with subsequent transformation to plasmablastic lymphoma and review the literature for transformed PCMZL to assess clinical and pathologic characteristics. In the case we describe, the patient presented with multifocal PCMZL, developed large B cell transformation with plasmacytic differentiation, followed by plasmablastic transformation (PBL), and ultimately died of disease progression despite multiple lines of therapy. Past history was significant for psoriatic arthritis (multiple prior lines of immunomodulatory therapy). The lymphomas and non-involved bone marrow share the same somatic DNMT3A and TET2 mutations, suggesting clonal relatedness and an association with clonal hematopoiesis (CH).
Results
Eighteen cases comprised the cohort (seventeen cases from the literature and the case reported herein). Nearly half of the eighteen cases of PCMZL with transformation died of progressive disease (44%). Transformed cases were more commonly seen in patients with >2 sites at initial diagnosis. EBV was assessed in 5 patients, 3 were positive (all died of disease). Two patients with NGS studies demonstrated TET2 and DNMT3A mutations.
Conclusions
Transformation of EBV positive PCMZL appears to be a poor prognostic indicator, with our reported case being the first well defined case transformed to PBL, suspected to arise from myeloid-CH.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pathology, Beckman Research Institute, City of Hope Medical Center, Duarte, CA, US.
- Department of Hematology and Hematopoietic Cell Transplant, Division of Lymphoma, Beckman Research Institute, City of Hope Medical Center, Duarte, CA, US.
- Department of Pathology, Division of Dermatology, Department of Hematology and Hematopoietic Cell Transplantation, and Beckman Research Institute, City of Hope Medical Center, Duarte, CA, US.
ORCID-Profile: Michelle Afkhami, Fei Fei
Förderung
- Department of Pathology, City of Hope Medical Center
Zitieren
APA
Soma, L., Crisan, L., Reid, J., Lee, W., Song, J., Afkhami, M., Shouse, G., Fei, F., Danilova, O., Pillai, R., Zain, J., & Querfeld, C. (2025). Epstein-Barr virus–positive, primary cutaneous marginal zone lymphoma, with transformation: Case report and review of the literature. American Journal of Clinical Pathology. https://doi.org/10.1093/ajcp/aqae124
Vancouver
Soma L, Crisan L, Reid J, Lee W, Song J, Afkhami M, et al. Epstein-Barr virus–positive, primary cutaneous marginal zone lymphoma, with transformation: Case report and review of the literature. American Journal of Clinical Pathology. 2025. doi:10.1093/ajcp/aqae124
BibTeX
@article{Soma2025,
author = {Soma, Lori and Crisan, Liliana and Reid, Jack and Lee, Winston and Song, Joo and Afkhami, Michelle and Shouse, Geoffrey and Fei, Fei and Danilova, Olga and Pillai, Raju and Zain, Jasmin and Querfeld, Christiane},
title = {Epstein-Barr virus–positive, primary cutaneous marginal zone lymphoma, with transformation: Case report and review of the literature},
journal = {American Journal of Clinical Pathology},
year = {2025},
doi = {10.1093/ajcp/aqae124}
}
EUVIMED